Standard BioTools Inc. LAB
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 170.46% | 158.91% | 46.07% | -2.94% | -1.56% |
| Total Depreciation and Amortization | -40.74% | -33.48% | -40.93% | 81.89% | -19.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -573.14% | -616.15% | 878.04% | 243.78% | 833.80% |
| Change in Net Operating Assets | -127.34% | -106.20% | -54.05% | 84.83% | 39.38% |
| Cash from Operations | 13.54% | 18.52% | 48.18% | 39.21% | 26.87% |
| Capital Expenditure | 81.90% | 69.76% | 0.62% | -121.92% | -239.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.49% | -100.49% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -483.15% | -310.92% | -61.55% | 49.48% | 75.91% |
| Cash from Investing | 415.99% | 241.36% | -92.45% | -81.14% | -87.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -482.50% | -435.28% |
| Issuance of Common Stock | 4.77% | -43.34% | -49.08% | -57.63% | -54.45% |
| Repurchase of Common Stock | -70.08% | 98.14% | 98.82% | 99.02% | 99.13% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Financing | 100.61% | 100.69% | 100.56% | -11.14% | -8.35% |
| Foreign Exchange rate Adjustments | -77.45% | 247.42% | 207.26% | 334.38% | 1,840.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 200.93% | 184.82% | -139.14% | -160.79% | -185.86% |